Fellows & Alumni

Academic clinicians with unique skill sets

The first cohort of MB-PhD students and CRTF has now been recruited.

Mairi Treanor-Taylor
Mairi is a first year MB-PhD student in the labs of Prof Gareth Inman (GLA) and Prof Charlie Gourley (EDI). Her project focuses on one of the main types of skin cancer, cutaneous squamous cell carcinoma, aiming to identify drivers and therapeutic vulnerabilities for its metastasis.
Read More


Tian En Lim
Tian En is a first year MB-PhD student working with Dr Simon Wilkinson (EDI) and Prof Neil Carragher (EDI). His project focuses on identifying drugs that promote the anti-tumour response of the immune system.

Read More


Lorna Stillie
Lorna is a first year MB-PhD student under the supervision of Prof Charlie Gourley (EDI) and Prof Gareth Inman (GLA). Her project focuses on the most common form of epithelial ovarian cancer. She is investigating the role of MAPK pathway – often defect in cancers this pathway can lead to uncontrolled growth.
Read More


Ryan Devlin
Ryan is a first year MB-PhD student in the labs of Dr Ed Roberts (GLA) and Dr Tak Kitamura (EDI). His project focuses on a phenomenon called myeloid skewing where immune cell production shifts towards the bone marrow. He is investigating how this affects the anti-tumour response of the immune system.
Read more


Michael Gillespie
Michael is a clinical research fellow in his second year of doctoral training under the supervision of Prof Owen Sansom (GLA). His project focuses understanding the response to radiotherapy treatment in rectal cancer. He is investigating the impact it has on the tumour microenvironment, in particular the immune system.
Read more


Douglas Cartwright
Doug is a clinical research fellow in his second year of doctoral training working with Prof Sara Zanivan (GLA) and Dr Rosalind Glasspool (GLA). His project focuses on the metabolic interplay between cancer-associated fibroblasts and tumour cells. Using cutting edge proteomics, he aims to identify vulnerabilities that can be exploited for therapy in ovarian carcinoma metastases.
Read more